Cost-effectiveness analysis of umeclidinium/vilanterol for the management of patients with moderate to very severe COPD using an economic model

BACKGROUND: Bronchodilators such as long-acting muscarinic antagonists (LAMAs) and long-acting β(2)-agonists (LABAs) are central to the pharmacological management of COPD. Dual bronchodilation with umeclidinium/vilanterol (UMEC/VI; 62.5/25 μg) is a novel LAMA/LABA combination approved for maintenanc...

Descripción completa

Detalles Bibliográficos
Autores principales: Wilson, Michele R, Patel, Jeetvan G, Coleman, Amber, McDade, Cheryl L, Stanford, Richard H, Earnshaw, Stephanie R
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Dove Medical Press 2017
Materias:
Original Research
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5373831/
https://www.ncbi.nlm.nih.gov/pubmed/28392684
http://dx.doi.org/10.2147/COPD.S124420

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5373831/
https://www.ncbi.nlm.nih.gov/pubmed/28392684
http://dx.doi.org/10.2147/COPD.S124420

Ejemplares similares